Iwagaki H, Fuchimoto S, Orita K
First Department of Surgery, Okayama University Medical School, Japan.
Acta Med Okayama. 1988 Jun;42(3):121-7. doi: 10.18926/AMO/31030.
The same chemotherapeutic agents were tested against fresh surgical explants of solid tumors obtained from 50 patients using the in vivo subrenal capsule (SRC) assay and the in vitro succinate dehydrogenase inhibition (SDI) test in comparison. Control growth adequate to meet evaluable assay criteria was obtained in 36 of the 50 tumors tested in the SRC assay (72.0%). In the SDI test, 46 of 50 tumors were evaluable (92.0%). Correlations between the two test systems were dependent upon the activity criteria established for each system. With activity criteria set at a change of less than or equal to -2.0 in the drug sensitivity score for the SRC assay and greater than or equal to 50.0% inhibition of succinate dehydrogenase activity for the SDI test, 12.5% of the drugs tested were active in the SRC assay and 22.3% were active in the SDI test. Correlations of tumor response between the two test systems were 31.7% for sensitivity (13/41) and 95.1% for resistance (98/103). In spite of the fundamental difference between the SRC assay and SDI test, meaningful correlations between the test results and clinical tumor responses in both test systems were obtained. This fact suggests that the two methods are complementary to each other.
使用体内肾包膜下（SRC）试验和体外琥珀酸脱氢酶抑制（SDI）试验，对从50例患者获取的实体瘤新鲜手术切除组织进行了相同化疗药物的测试，并进行比较。在SRC试验中测试的50个肿瘤中，有36个（72.0%）获得了足以满足可评估试验标准的对照生长。在SDI试验中，50个肿瘤中有46个可评估（92.0%）。两个测试系统之间的相关性取决于为每个系统设定的活性标准。将SRC试验的药物敏感性评分变化设定为小于或等于-2.0，以及将SDI试验的琥珀酸脱氢酶活性抑制设定为大于或等于50.0%作为活性标准时，所测试药物中12.5%在SRC试验中有活性，22.3%在SDI试验中有活性。两个测试系统之间肿瘤反应的相关性在敏感性方面为31.7%（13/41），在耐药性方面为95.1%（98/103）。尽管SRC试验和SDI试验存在根本差异，但在两个测试系统中均获得了测试结果与临床肿瘤反应之间有意义的相关性。这一事实表明这两种方法相互补充。
